Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study

Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: I...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Pietrantonio, Maria, Brescini, Lucia, Candi, Jennifer, Gianluca, Morroni, Pallotta, Francesco, Mazzanti, Sara, Mantini, Paolo, Candelaresi, Bianca, Olivieri, Silvia, Ginevri, Francesco, Cesaretti, Giulia, Castelletti, Sefora, Cocci, Emanuele, Polo, Rosaria G., Cerutti, Elisabetta, Simonetti, Oriana, Cirioni, Oscar, Tavio, Marcello, Giacometti, Andrea, Barchiesi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944595/
https://www.ncbi.nlm.nih.gov/pubmed/35326784
http://dx.doi.org/10.3390/antibiotics11030321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944595/
https://www.ncbi.nlm.nih.gov/pubmed/35326784
http://dx.doi.org/10.3390/antibiotics11030321

Ejemplares similares